Key result
Cardiac myocyte injury, renal function, and inflammation markers are promising biomarkers for predicting incident atrial fibrillation and cardiovascular events in patients with metabolic syndrome.
Why the study?
Do circulating biomarkers predict incident atrial fibrillation or cardiovascular events in patients with metabolic syndrome?
Do circulating biomarkers predict incident atrial fibrillation or cardiovascular events in patients with metabolic syndrome?
Circulating biomarkers of cardiac injury, renal function, and inflammation show promise for refining risk prediction of incident AF and cardiovascular events in patients with metabolic syndrome.
May refine AF risk stratification in metabolic syndrome; hypothesis-generating and requires prospective validation before practice change.
Whether the increased atrial fibrillation (AF) risk in metabolic syndrome (MetS) patients is due to the syndrome as a whole or simply the sum of the risks of its individual component parts is still obscure. These two clinical entities share many pathophysiological links and thus distinction between a casual observation and a significant association is difficult. Biomarkers associated with pathogenesis of AF in the context of MetS have the ability to refine future risk prediction. In the present review we identify circulating substances that could be regarded as potential biomarkers for prediction of incident AF, or of cardiovascular events in the setting of AF in patients with MetS. Cardiac myocyte injury and stress markers (troponin and natriuretic peptides), markers of renal function (glomeral filtration rate, cystatin-C), and inflammation markers/mediators (interleukin- 6, CRP) are promising biomarkers of patients with AF and MetS.
No takes yet. Share an insight, caveat, or question.
Georgakopoulos et al. (2017) conducted a review in Atrial fibrillation in metabolic syndrome. Biomarkers was evaluated on Incident atrial fibrillation or cardiovascular events. Cardiac myocyte injury, renal function, and inflammation markers are promising biomarkers for predicting incident atrial fibrillation and cardiovascular events in patients with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: